HWMvL reports (all payments are made to their institution): a consultant or advisory role for AstraZeneca, Beigene, BMS, and MSD (all related to checkpoint inhibitors) and for Amphera, Daiichi-Sankyo, Dragonfly, Eli Lilly, Nordic Pharma, and Servier; research funding, medication supply, or both from Incyte, Merck, Roche, and Servier (all related to checkpoint inhibitors) and from Bayer, BMS, Celgene, Janssen, Eli Lilly, Nordic Pharma, and Philips; and speaker roles for Astellas (related to checkpoint inhibitors), Benecke, Daiichi-Sankyo, JAAP, Medtalks, Novartis, and Travel Congress Management. SD reports: a consultant or advisory role for BMS (related to checkpoint inhibitors); research funding, medication supply, or both from Incyte (related to checkpoint inhibitors); and speaker roles for Servier, BMS, and Benecke.